Business Context and Reporting Period
Acadia Healthcare Company, Inc. filed a Form 8-K on April 21, 2020, reporting the entry into a material definitive agreement. The filing details a Thirteenth Amendment to the Company's Amended and Restated Credit Agreement, originally dated December 31, 2012.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, or liquidity metrics. The primary financial data presented relates to debt covenant thresholds.
| Fiscal Quarter Ending | Pre-Amendment Max Leverage Ratio | Post-Amendment Max Leverage Ratio |
|---|---|---|
| June 30, 2020 | 5.75x | 6.50x |
| September 30, 2020 | 5.75x | 6.50x |
| December 31, 2020 | 5.50x | 6.25x |
| March 31, 2021 | 5.25x | 5.25x |
| June 30, 2021 | 5.25x | 5.25x |
| September 30, 2021 and thereafter | 5.00x | 5.00x |
Material Changes
The Company amended its credit agreement to increase the maximum allowable consolidated leverage ratio for the next three fiscal quarters (ending June 30, 2020, through December 31, 2020). This adjustment provides temporary flexibility in debt covenants, likely in response to market conditions or operational impacts during the reporting period.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or specific risk factors beyond the context of the covenant amendment. The document notes that the summary is qualified by reference to the full Amendment attached as Exhibit 10.
Investor Verification Checklist
- Review the full text of the Thirteenth Amendment (Exhibit 10) for additional terms or conditions not summarized in the 8-K.
- Verify the Company's current consolidated leverage ratio to assess proximity to the new covenant limits.
- Monitor subsequent filings for any further amendments or covenant waivers related to the credit agreement.
- Confirm if the leverage ratio increase was triggered by specific financial performance issues or proactive liquidity management.